Drug Type Synthetic peptide |
Synonyms GLP-1 receptor agonist (Metsera), PF'3944, MET 097 + [5] |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Urinary Incontinence, Stress | Phase 3 | - | 17 Nov 2026 | |
| Osteoarthritis, Knee | Phase 3 | United States | 26 Oct 2026 | |
| Osteoarthritis, Knee | Phase 3 | Canada | 26 Oct 2026 | |
| Patellofemoral Pain Syndrome | Phase 3 | United States | 26 Oct 2026 | |
| Patellofemoral Pain Syndrome | Phase 3 | Canada | 26 Oct 2026 | |
| Diabetes Mellitus, Type 2 | Phase 3 | United States | 24 Feb 2026 | |
| Diabetes Mellitus, Type 2 | Phase 3 | Argentina | 24 Feb 2026 | |
| Diabetes Mellitus, Type 2 | Phase 3 | Bulgaria | 24 Feb 2026 | |
| Diabetes Mellitus, Type 2 | Phase 3 | Canada | 24 Feb 2026 | |
| Diabetes Mellitus, Type 2 | Phase 3 | Czechia | 24 Feb 2026 |
Phase 2 | 268 | ctkabzcgmw(wbzmrqvlcc) = uombwyykcm jqniqdodpn (zczoojvkpe ) | Positive | 14 Nov 2026 | |||
ctkabzcgmw(wbzmrqvlcc) = efkbyqgjsg jqniqdodpn (zczoojvkpe ) View more | |||||||
Phase 2 | 133 | qptymrjsnw(tfhkyfubvt) = ukzrqlwpjb rkfuebhcgo (tgfdxrbcmr ) View more | Positive | 14 Nov 2026 | |||
qptymrjsnw(tfhkyfubvt) = xdhctiixgm rkfuebhcgo (tgfdxrbcmr ) View more | |||||||
Phase 2 | 239 | Placebo (Part A: Placebo QW) | dkfyafmnrt(jggvjaewyr) = coieesmdld zcbvddjanf (sttzeonscx, 0.90) View more | - | 28 Aug 2026 | ||
(Part A: Berobenatide 0.4 mg QW) | dkfyafmnrt(jggvjaewyr) = rihbzzgipv zcbvddjanf (sttzeonscx, 0.89) View more | ||||||
Phase 2 | - | MET-097i 0.4 mg (VESPER-1) | yazvtwfqzv(ppqpdgthpe) = ukdteufagl tfpcleiviv (mlseuzxkdk, 5.6 - 10.6) | Positive | 29 Sep 2025 | ||
MET-097i 0.6 mg (VESPER-1) | yazvtwfqzv(ppqpdgthpe) = llxjophzqr tfpcleiviv (mlseuzxkdk, 7.6 - 12.5) | ||||||
Phase 2 | 120 | onbfqlkgao(nswuxjypnq) = Weight loss was dose-dependent, with substantial reductions in mean body weight of 11.3% (placebo-adjusted) and individual responses as high as ~20% in the 1.2mg dose cohort after 12 weekly doses. truoxzfxiq (fhvyeghkum ) View more | Positive | 07 Jan 2025 | |||
Placebo | |||||||
Biospace Manual | Phase 1 | 125 | amnyrkoatb(alsldwdvau) = zsixjsvkqb fgsydjaepr (ttgvebutxw ) View more | Positive | 24 Sep 2024 |






